Skip to main
ZBIO
ZBIO logo

ZBIO Stock Forecast & Price Target

ZBIO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zenas BioPharma Inc. is positioned to capture a significant portion of the estimated $3 billion market opportunity in IgG4-RD, driven by its innovative I&I product candidate, obexelimab, which employs a novel bifunctional monoclonal antibody approach. The company remains well-capitalized with approximately $350 million on its balance sheet, allowing for continued investment in clinical development and potential market expansion. As multiple catalyst events are expected over the next 18 months, Zenas BioPharma's outlook appears increasingly favorable, highlighting the promising efficacy differentiation of obexelimab in treating autoimmune diseases.

Bears say

Zenas BioPharma Inc. reported a substantial net loss of $52.6 million for the fourth quarter of 2024 and a cumulative loss of $157.0 million for the entire year, highlighting significant financial strain. The company's current valuation is concerning, trading at an enterprise value of approximately $15 million, which reflects investor skepticism regarding the future viability of its obexelimab candidate, particularly given the risks associated with unmet peak commercial revenue expectations and the need for ongoing capital to fund operations. The anticipated Phase 2 MoonStone topline results in 3Q25 create additional uncertainty, as any developmental failures or safety concerns could exacerbate the company's financial challenges and competitive positioning in the biopharmaceutical market.

ZBIO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zenas Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zenas Biopharma Inc (ZBIO) Forecast

Analysts have given ZBIO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ZBIO has a Strong Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zenas Biopharma Inc (ZBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.